Zydus Cadila gets USFDA nod for multiple sclerosis drug
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the U.S. Food and Drug Administration (USFDA) to market Dimethyl Fumarate DelayedRelease Capsules, (US RLD: Tecfidera®) in the strengths of 120 mg and 240 mg.
Dimethyl Fumarate Delayed-Release Capsules are indicated for the treatment of patients with relapsing forms of multiple sclerosis and will be manufactured at the group's manufacturing facility at the SEZ, Matoda.
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.